FOLH1 and meningioma: Recently, results of a large retrospective cohort of mCRPC patients treated with the ɑ emitter-based radioligand [225Ac]Ac-PSMA were published, showing antitumoral activity at an acceptable side effect profile.84 In NETs previously treated with 177Lu-based agents, [225Ac]Ac-DOTATATE showed promising results in early pilot studies,85,86 but data in meningioma are lacking so far.